生物性改善病情抗风湿药物的感染风险
Infection Risk in Biological Disease-Modifying Anti-rheumatic Drugs.
作者信息
Isa Mourushi, Ramos Ma Rosario Rufina, Kamal Shahed
机构信息
General Medicine, Northern Health, Melbourne, AUS.
Medicine, Ateneo School of Medicine and Public Health, Pasig, PHL.
出版信息
Cureus. 2025 Mar 15;17(3):e80634. doi: 10.7759/cureus.80634. eCollection 2025 Mar.
Abstract
Rheumatology patients on biological disease-modifying anti-rheumatic drugs (bDMARDs) have been proposed to be at a higher risk of infections. Our review summarizes the current evidence behind this theory as well as explores which factors predispose patients to various infections, which agents are more likely to cause infections, and which infections are common in these patients. We also aim to explore updated guidelines on infection prevention in patients on bDMARDs.
摘要
有观点认为，使用生物性改善病情抗风湿药（bDMARDs）的风湿病患者感染风险更高。我们的综述总结了这一理论背后的现有证据，并探讨了哪些因素使患者易发生各种感染、哪些药物更易导致感染以及这些患者中常见哪些感染。我们还旨在探索bDMARDs治疗患者感染预防的最新指南。
相似文献
1
Infection Risk in Biological Disease-Modifying Anti-rheumatic Drugs.
Cureus. 2025 Mar 15;17(3):e80634. doi: 10.7759/cureus.80634. eCollection 2025 Mar.
2
Frequency of severe infections in rheumatic disease patients receiving bDMARDs post-kidney transplantation: a multicenter study.
Clin Rheumatol. 2025 Feb;44(2):831-838. doi: 10.1007/s10067-024-07287-7. Epub 2024 Dec 24.
3
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Expert Rev Clin Immunol. 2020 Feb;16(2):207-228. doi: 10.1080/1744666X.2019.1705785. Epub 2020 Jan 11.
4
Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
BMC Musculoskelet Disord. 2016 Dec 12;17(1):499. doi: 10.1186/s12891-016-1354-7.
5
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001439.
6
[Perioperative management of treatment of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society of Rheumatology].
Z Rheumatol. 2022 Apr;81(3):212-224. doi: 10.1007/s00393-021-01140-x. Epub 2021 Dec 20.
7
Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs: A comparative study.
J Family Med Prim Care. 2022 Jul;11(7):3575-3583. doi: 10.4103/jfmpc.jfmpc_2147_21. Epub 2022 Jul 22.
8
The Effect of Perioperative Biologic Disease-Modifying Anti-Rheumatic Drugs on the Risk of Postoperative Complications: Surgical Site Infection, Delayed Wound Healing, and Disease Flares Following Orthopaedic Surgical Procedures.
J Bone Joint Surg Am. 2022 Jun 15;104(12):1116-1126. doi: 10.2106/JBJS.21.00811. Epub 2022 Feb 17.
10
2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Int J Rheum Dis. 2017 Sep;20(9):1166-1184. doi: 10.1111/1756-185X.13130. Epub 2017 Jul 21.
本文引用的文献
1
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Nat Commun. 2024 Oct 25;15(1):9230. doi: 10.1038/s41467-024-53384-1.
2
Risk for latent tuberculosis infection reactivation among patients with psoriasis on biologics treatment: A meta-analysis.
J Infect. 2024 Sep;89(3):106226. doi: 10.1016/j.jinf.2024.106226. Epub 2024 Jul 8.
3
Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
Joint Bone Spine. 2024 May;91(3):105673. doi: 10.1016/j.jbspin.2023.105673. Epub 2023 Nov 30.
4
Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis.
Cancers (Basel). 2023 Apr 7;15(8):2197. doi: 10.3390/cancers15082197.
5
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Ann Rheum Dis. 2023 Jul;82(7):911-919. doi: 10.1136/ard-2022-223636. Epub 2023 Mar 3.
6
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.
7
Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Arthritis Res Ther. 2022 Jul 28;24(1):180. doi: 10.1186/s13075-022-02871-1.
8
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927.
9
Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults.
Rheumatology (Oxford). 2021 Nov 3;60(11):5042-5051. doi: 10.1093/rheumatology/keab538.
10
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
Ann Rheum Dis. 2022 Jan;81(1):41-47. doi: 10.1136/annrheumdis-2021-220651. Epub 2021 Jul 28.
Zotero 插件